Was expired Remdesivir linked to Nipah deaths in Kerala? Cloud over batches used over 3 years

The medical board will investigate a possible link between expired Remdesivir and deaths among Kerala’s Nipah patients. It must determine whether patients received vials after their expiry date and whether that treatment contributed to their deaths. The investigation does not yet establish that expired medicine caused any death.

The key concern comes from Kozhikode Medical College records. The hospital reported using 102 vials in 2023–24, 34 in 2024–25, and 10 in 2025–26. The last KMSCL purchase was on June 3, 2021, and those 3,000 vials expired on May 30, 2023. These dates raised suspicion about possible use in later years.

Health Minister K Muraleedharan announced the probe in the Legislative Assembly. The medical education and health services directorates must collect records from hospitals and patients who received Remdesivir. That broader review should clarify which batches were administered, when they were used, and whether any deaths involved expired vials.

A medicine batch is expired when it has passed the date printed by its manufacturer for acceptable quality. Until that date, the manufacturer guarantees its strength, purity, and performance under specified storage conditions. Afterward, those guarantees no longer apply. Expiry is attached to a batch, so different batches can have different dates.

This matters because a patient may receive too little active medicine if the drug has weakened. Chemical breakdown can also create unwanted substances, although the exact risk depends on the medicine and its storage. For a critically ill person, reduced antiviral activity could mean treatment does not work as intended. Expiry alone, however, does not prove that a medicine caused harm.

In Kerala, the questioned Remdesivir batches were purchased in 2021 and listed as expiring May 30, 2023. The investigation must match batch numbers, dates, and patient records. Doctors can then assess whether any expired doses were given and whether they plausibly affected outcomes.

Kerala reported six Nipah cases in 2023, two in 2024, and three in 2025. That totals 11 cases. Deaths numbered two in 2023, two in 2024, and two in 2025, for six deaths overall. The article also notes that the single case reported in 2026 survived.

The number of patients who may have received Remdesivir is not given. Kozhikode Medical College reported using 102 vials during 2023–24, 34 during 2024–25, and 10 during 2025–26. Those are vial counts, not patient counts, and the article does not identify how many Nipah patients received them. One patient in 2026 received vials brought from Bahrain.

The health authorities therefore need to collect patient-level records. They have been asked to identify everyone administered Remdesivir across government hospitals. That review may establish which of the 11 patients received the medicine and whether any received expired batches.

Doctors would need to verify that a patient actually received an expired Remdesivir vial. That requires the patient’s medication chart, administration date, vial or batch number, expiry date, dose, and storage history. They would also review the patient’s condition before treatment, laboratory results, organ function, and timeline of deterioration.

The key mechanism is causal comparison. Investigators would ask whether the medicine could have been ineffective or harmful, whether the patient worsened after receiving it, and whether another explanation better fits the evidence. They would consider Nipah severity, complications, other medicines, and any underlying illness. A death occurring after treatment does not by itself show that treatment caused it.

Kerala has not reported such a conclusion. The announced medical board and hospital record review are intended to establish the facts. They can compare treatment records with the six Nipah deaths in 2023–25 and determine whether expired Remdesivir plausibly contributed.

Remdesivir is an antiviral medicine. The article says it was prescribed for treatment during India’s Covid-19 pandemic. In general medical use, it is intended to slow viral multiplication by interfering with an enzyme viruses need to copy their genetic material. That can give the body more opportunity to control the infection.

Its effect depends on the virus, the timing of treatment, the dose, and the patient’s condition. It is not an antibiotic, so it does not target bacteria. For Nipah patients, the article focuses on whether Remdesivir was administered, not on proving that it works against Nipah. Its use in the reported cases is therefore part of the investigation.

The medicine is patented and manufactured in India under voluntary licences granted by Gilead Life Sciences USA to Indian pharmaceutical companies. Kerala obtained Remdesivir for government hospitals through KMSCL. The probe will examine whether some administered vials had passed their expiry date.

After a medicine’s expiry date, its manufacturer no longer guarantees its strength, purity, or performance. The active ingredient may gradually break down, reducing the intended dose. In some medicines, degradation can also produce impurities. The exact outcome differs by drug and formulation, so expiry does not automatically mean immediate poisoning or complete loss of activity.

Storage conditions matter because heat, moisture, freezing, and light can damage medicines. Poor handling may shorten their usable life, while correct storage helps preserve quality until the labelled expiry date. Hospitals therefore track batches, temperatures, stock movement, and administration dates. These records are especially important when a medicine is used for a severe infection.

The Kerala investigation must determine how Remdesivir was stored and administered. The last KMSCL purchase had an expiry date of May 30, 2023, but Kozhikode reported later vial use. The medical board must assess whether any affected vials had degraded and whether that mattered clinically.

Nipah virus is a virus that can cause serious human illness. The article identifies it as a deadly virus and reports deaths among Kerala patients in 2023, 2024, and 2025. It does not provide a detailed medical definition or explain the disease’s biological mechanism, so those details come from established medical knowledge.

In general, Nipah infection can cause severe inflammation and injury in the brain, along with serious breathing problems. These effects can disrupt essential body functions and may progress rapidly. The danger varies by patient and illness severity. A patient’s death therefore cannot automatically be attributed to a medicine given during treatment.

Kerala recorded six cases in 2023, two in 2024, and three in 2025. Two patients died in each of those years. The state’s probe will examine whether expired Remdesivir contributed to any deaths, while recognising that Nipah itself can be fatal. One reported case in 2026 survived.